133 related articles for article (PubMed ID: 32857419)
1. Evaluation of designs for renal drug studies based on the European Medicines Agency and Food and Drug Administration guidelines for drugs that are predominantly secreted.
Pradhan S; Wright DFB; Duffull SB
Br J Clin Pharmacol; 2021 Mar; 87(3):1401-1410. PubMed ID: 32857419
[TBL] [Abstract][Full Text] [Related]
2. EMA and FDA psychiatric drug trial guidelines: assessment of guideline development and trial design recommendations.
Boesen K; Gøtzsche PC; Ioannidis JPA
Epidemiol Psychiatr Sci; 2021 Apr; 30():e35. PubMed ID: 33926608
[TBL] [Abstract][Full Text] [Related]
3. Update and trends on pharmacokinetic studies in patients with impaired renal function: practical insight into application of the FDA and EMA guidelines.
Paglialunga S; Offman E; Ichhpurani N; Marbury TC; Morimoto BH
Expert Rev Clin Pharmacol; 2017 Mar; 10(3):273-283. PubMed ID: 27998190
[TBL] [Abstract][Full Text] [Related]
4. The intact nephron hypothesis as a model for renal drug handling.
Pradhan S; Duffull SB; Walker RJ; Wright DFB
Eur J Clin Pharmacol; 2019 Feb; 75(2):147-156. PubMed ID: 30298363
[TBL] [Abstract][Full Text] [Related]
5. Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency.
Levey AS; Gansevoort RT; Coresh J; Inker LA; Heerspink HL; Grams ME; Greene T; Tighiouart H; Matsushita K; Ballew SH; Sang Y; Vonesh E; Ying J; Manley T; de Zeeuw D; Eckardt KU; Levin A; Perkovic V; Zhang L; Willis K
Am J Kidney Dis; 2020 Jan; 75(1):84-104. PubMed ID: 31473020
[TBL] [Abstract][Full Text] [Related]
6. Food and Drug Administration vs European Medicines Agency: Review times and clinical evidence on novel drugs at the time of approval.
Joppi R; Bertele V; Vannini T; Garattini S; Banzi R
Br J Clin Pharmacol; 2020 Jan; 86(1):170-174. PubMed ID: 31657044
[TBL] [Abstract][Full Text] [Related]
7. Does Secretory Clearance Follow Glomerular Filtration Rate in Chronic Kidney Diseases? Reconsidering the Intact Nephron Hypothesis.
Chapron A; Shen DD; Kestenbaum BR; Robinson-Cohen C; Himmelfarb J; Yeung CK
Clin Transl Sci; 2017 Sep; 10(5):395-403. PubMed ID: 28675584
[TBL] [Abstract][Full Text] [Related]
8. To what degree are review outcomes aligned for new active substances (NASs) between the European Medicines Agency and the US Food and Drug Administration? A comparison based on publicly available information for NASs initially approved in the time period 2014 to 2016.
Kühler TC; Bujar M; McAuslane N; Liberti L
BMJ Open; 2019 Nov; 9(11):e028677. PubMed ID: 31772082
[TBL] [Abstract][Full Text] [Related]
9. The Food and Drug Administration reports provided more data but were more difficult to use than the European Medicines Agency reports.
Schroll JB; Abdel-Sattar M; Bero L
J Clin Epidemiol; 2015 Jan; 68(1):102-7. PubMed ID: 25150193
[TBL] [Abstract][Full Text] [Related]
10. An Exact Procedure for the Evaluation of Reference-Scaled Average Bioequivalence.
Tothfalusi L; Endrenyi L
AAPS J; 2016 Mar; 18(2):476-89. PubMed ID: 26831249
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the EMA and FDA Guidelines on Ulcerative Colitis Drug Development.
Reinisch W; Gottlieb K; Colombel JF; Danese S; Panaccione R; Panes J; Peyrin-Biroulet L; Rubin D; Sands BE; Schreiber S; Vermeire S; Mulberg A; Sandborn B
Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1673-1679.e1. PubMed ID: 31352970
[TBL] [Abstract][Full Text] [Related]
12. Do the EMA accelerated assessment procedure and the FDA priority review ensure a therapeutic added value? 2006-2015: a cohort study.
Boucaud-Maitre D; Altman JJ
Eur J Clin Pharmacol; 2016 Oct; 72(10):1275-1281. PubMed ID: 27473682
[TBL] [Abstract][Full Text] [Related]
13. New drug submissions in Canada and a comparison with the Food and Drug Administration and the European Medicines Agency: Cross-sectional analysis.
Lexchin J
PLoS One; 2023; 18(6):e0286802. PubMed ID: 37319240
[TBL] [Abstract][Full Text] [Related]
14. Priority review drugs approved by the FDA and the EMA: time for international regulatory harmonization of pharmaceuticals?
Alqahtani S; Seoane-Vazquez E; Rodriguez-Monguio R; Eguale T
Pharmacoepidemiol Drug Saf; 2015 Jul; 24(7):709-15. PubMed ID: 26013294
[TBL] [Abstract][Full Text] [Related]
15. Assessment of PRO label claims granted by the FDA as compared to the EMA (2006-2010).
DeMuro C; Clark M; Doward L; Evans E; Mordin M; Gnanasakthy A
Value Health; 2013 Dec; 16(8):1150-5. PubMed ID: 24326168
[TBL] [Abstract][Full Text] [Related]
16. Canadian, European and United States new drug approval times now relatively similar.
Rawson NSB
Regul Toxicol Pharmacol; 2018 Jul; 96():121-126. PubMed ID: 29730446
[TBL] [Abstract][Full Text] [Related]
17. Updated US and European Dose Recommendations for Intravenous Colistin: How Do They Perform?
Nation RL; Garonzik SM; Li J; Thamlikitkul V; Giamarellos-Bourboulis EJ; Paterson DL; Turnidge JD; Forrest A; Silveira FP
Clin Infect Dis; 2016 Mar; 62(5):552-558. PubMed ID: 26607424
[TBL] [Abstract][Full Text] [Related]
18. Bioequivalence for highly variable drugs: regulatory agreements, disagreements, and harmonization.
Endrenyi L; Tothfalusi L
J Pharmacokinet Pharmacodyn; 2019 Apr; 46(2):117-126. PubMed ID: 30798390
[TBL] [Abstract][Full Text] [Related]
19. Quantitative analysis of drug handling by the kidney using a physiological model of renal drug clearance.
Janků I; Zvára K
Eur J Clin Pharmacol; 1993; 44(6):521-4. PubMed ID: 8405005
[TBL] [Abstract][Full Text] [Related]
20. A Review of Patient-Reported Outcomes Labeling for Oncology Drugs Approved by the FDA and the EMA (2012-2016).
Gnanasakthy A; Barrett A; Evans E; D'Alessio D; Romano CD
Value Health; 2019 Feb; 22(2):203-209. PubMed ID: 30711065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
